120 related articles for article (PubMed ID: 8435662)
1. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.
Jiang YZ; Cullis JO; Kanfer EJ; Goldman JM; Barrett AJ
Bone Marrow Transplant; 1993 Feb; 11(2):133-8. PubMed ID: 8435662
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells.
Jiang YZ; Kanfer EJ; Macdonald D; Cullis JO; Goldman JM; Barrett AJ
Bone Marrow Transplant; 1991 Oct; 8(4):253-8. PubMed ID: 1756322
[TBL] [Abstract][Full Text] [Related]
3. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
[TBL] [Abstract][Full Text] [Related]
4. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
5. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
[TBL] [Abstract][Full Text] [Related]
6. [Donor leukocyte transfusion in a patient with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation: analysis of natural killer cell activity and T-cell receptor repertoire in bone marrow T cells that exhibited graft-versus-leukemia activity].
Suehiro Y; Muta K; Umemura T; Motomura S; Nishimura J; Nawata H; Kimura N
Rinsho Ketsueki; 1999 Jan; 40(1):40-5. PubMed ID: 10067095
[TBL] [Abstract][Full Text] [Related]
7. Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help?
Hughes TP; Goldman JM
Bone Marrow Transplant; 1990 Jan; 5(1):3-6. PubMed ID: 2404529
[TBL] [Abstract][Full Text] [Related]
8. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
10. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
13. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
14. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
15. Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.
Bunjes D; Theobald M; Hertenstein B; Wiesneth M; Novotny J; Arnold R; Heimpel H
Bone Marrow Transplant; 1995 May; 15(5):713-9. PubMed ID: 7670400
[TBL] [Abstract][Full Text] [Related]
16. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
17. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
19. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
[TBL] [Abstract][Full Text] [Related]
20. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
